ACM
AIMT

AlphaCrest Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

AlphaCrest Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-9,000
Closed -$301K – 1374
2019
Q4 		$301K Buy
+9,000
New +$252K 0.02% 1060
2019
Q3 		– Sell
-11,400
Closed -$237K – 1386
2019
Q2 		$237K Buy
+11,400
New +$235K 0.02% 930

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AlphaCrest Capital Management's AIMT Position: Q1 2020 in Review

AlphaCrest Capital Management sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 9,000 shares — an estimated $301K sold.

AlphaCrest Capital Management first reported a position in AIMT in Q2 2019 and held it in 2 quarters. The position peaked at $301K in Q4 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

  • AlphaCrest Capital Management reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • AlphaCrest Capital Management sold 9,000 Aimmune Therapeutics shares in Q1 2020, an estimated $301K.
  • AlphaCrest Capital Management first reported a position in Aimmune Therapeutics in Q2 2019 and held it in 2 quarters.
  • AlphaCrest Capital Management's Aimmune Therapeutics position peaked at $301K in Q4 2019.
  • 161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on AlphaCrest Capital Management's 13F filing for Q1 2020, filed 13 May 2020.